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Edging ever closer to polio eradication
After the triumphant announcement of the eradication 
of smallpox in 1980 to the World Health Assembly, the 
WHO soon switched its attention to polio prevention, 
instigating in 1988 the Global Polio Eradication 
Initiative—a highly productive public–private part-
nership between WHO, Rotary International, the US 
Centers for Disease Control and Prevention, UNICEF, and 
the Bill & Melinda Gates Foundation. By 1999, reports 
of wild type 2 polio had ceased, while type 3 disease 
left the world stage in 2012: impressive progress. 
Polio of any type has even stopped circulating in the 
hitherto strongholds of India and Nigeria; the last cases 
were reported in 2011 and 2014, respectively. Polio 
remains endemic only along the border of Pakistan and 
Afghanistan. Eradication seems in our grasp.
However, in May, 2012, the World Health Assembly 
noted an alarming reduction in control eﬀ orts by many 
at-risk countries and declared (the completion of) polio 
eradication to be a global public health emergency.1 
Recent successes had been tempered by the emergence 
of vaccine-derived polio viruses. Preventing the 
circulation of such viruses has become a pressing issue, 
especially type 2 which accounts for the great majority 
of isolates. In 2012, the WHO’s Strategic Advisory Group 
of Experts on immunization promulgated a polio end-
game strategy with some decisive recommendations 
whereby the “highest possible immunity” be achieved 
with one additional dose of inactivated polio vaccine 
(IPV) in concert with an “unchanged OPV routine 
schedule”, but without the type 2 component in the 
oral polio vaccine (OPV). Beginning from April, 2016, 
a bivalent (types 1 and 3) OPV was to be substituted 
for the trivalent OPV, while delivering one dose of IPV 
concurrently with the third dose of bivalent OPV in the 
infant schedule.2,3
In The Lancet Global Health, Ed Clarke and colleagues4 
report a large, complex, but elegant phase 4 non-
inferiority randomised trial in Gambian infants on the 
safety and immunogenicity of IPV given at age 9 months 
concurrently with a measles and rubella combined 
vaccine and yellow fever vaccine. Two diﬀ erent routes of 
administration were also assessed. A key study rationale 
derives from Clarke and colleagues’ assertion that a second 
dose of IPV might be needed to optimise disease control 
in countries at risk of polio resurgence. For programmatic 
and immunological reasons, the likely best opportunity 
to deliver a second dose of IPV would be at age 9 months, 
when measles-rubella vaccination is already being 
delivered, as is yellow fever vaccine in countries with 
endemic yellow fever. The primary objective was to 
assess safety and to test for immunological interference 
associated with co-administration of IPV, measles-rubella, 
and yellow fever vaccines. Clarke and colleagues hoped 
to demonstrate non-inferiority of immune responses to 
concurrently delivered vaccines (IPV and measles-rubella; 
IPV and yellow fever; measles-rubella and yellow fever; 
and IPV, measles-rubella, and yellow fever) in comparison 
with study groups in which each of the three vaccines 
was given alone. The secondary objective was to address 
the immunogenicity and safety of IPV, full dose (0·5 mL) 
and fractional dose (0·1 mL), administered in the standard 
way by needle and syringe, or by disposable-syringe-jet-
injector.
Dealing with straightforward issues ﬁ rst, all the 
vaccinations were well tolerated, with low levels of both 
local and systemic reactogenicity. Furthermore, global 
non-inferiority was shown for all the combinations 
of vaccines on the basis of seroprevalence and 
seroconversion data. However, examination of antibody 
titres found that not one vaccine combination achieved 
non-inferiority compared to the groups where each 
vaccine was given alone. This was due to reduced titres 
against both rubella and yellow fever upon any co-
administration. The eﬀ ect was greatest in the group 
in which all three vaccines were co-administered. By 
contrast, measles and polio responses were not reduced 
when vaccines were concurrently delivered.
Several concerns arise. Yellow fever vaccine is thought 
to induce long-term, probably lifelong, immunity but 
it is unclear whether the interference induced by co-
administration will alter this. Continuing to observe 
the practice of giving a yellow fever vaccine booster 
every 10 years (or more) may obviate this concern, but 
that would be a backward step. Furthermore, reduced 
immunity to rubella may increase the proportion of 
at-risk females who enter the childbearing band and 
heighten the risk of congenital rubella syndrome. WHO 
recommends at least 80% coverage for each birth 
cohort, but more when rubella transmission is high or 
vaccine immunogenicity is reduced.5
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The case for a second dose of IPV at 9 months, as 
outlined in this paper, is not compelling, but rejecting 
this new approach to vaccine delivery (and potentially 
improved disease control) because a subset of non-
inferiority determinations are not achieved risks 
throwing out the baby with the bathwater. Given that 
this trial is the ﬁ rst to examine co-administration of IPV 
with measles-rubella and yellow fever vaccines (as well 
as measles-rubella and yellow fever co-administration), 
further work is certainly warranted, including studies 
in which a ﬁ rst dose of IPV is given at 3–4 months 
concurrently with the third OPV.
The responses to fractional dosing with IPV by either 
needle-and-syringe or disposable-syringe-jet-injector 
were reduced compared to the full dose. Clarke and 
colleagues soberly note that their data do not support 
implementation or widespread use of fractional doses, 
other than perhaps in an outbreak.
There is clearly intense interest by WHO, the Bill & 
Melinda Gates Foundation, and other organisations 
in improving the immunogenicity and practical 
deliverability of IPV vaccines. The recent publication of 
microneedle approaches in animals, achieving dose-
sparing in at least one model, is encouraging and may 
lead to immunologically superior and more practical 
results in infants than using a jet injector to deliver 
vaccine intradermally.6,7
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